Nirsevimab and Acute Bronchiolitis Episodes in Pediatric Emergency Departments
- David Martínez; Gemma Teruel; Manuel Mediavilla; Amaia Otegui; Laura López; Begoña de Miguel Lavisier
Access Resources
About
The study looks at how nirsevimab, a medicine given to babies in Spain during the 2023-2024 RSV season, affected visits to emergency rooms for breathing problems. It describes a big drop in cases of lower respiratory infections and bronchiolitis compared to past years. Hospital admissions and intensive care needs also went down by over 60%. Regions that gave the medicine to more babies saw even better results. The study suggests nirsevimab is very effective at protecting infants from RSV but notes that cost should be considered when using this approach widely.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.